|
- Serotonin toxicity (syndrome) and triptans | Migraine Foundation . . .
Triptans bind to serotonin receptors, so it’s understandable why this might be a concern The warning about an interaction between triptans and SRIs originated from the US Food and Drug Administration in 2006, based on a case series which has since been roundly critiqued as invalid
- Sumatriptan poisoning and its clinical presentation in humans: A case . . .
In February 2022, a 20‐year‐old bodybuilder man presented to the emergency department with unusual sweating, agitation, hallucination, and urine and fecal incontinency
- Forecasting liver toxicity before the damage is done
Using toxicity data from thousands of chemicals, researchers developed a computational program that predicts whether a drug candidate is likely to cause liver damage
- Real-world study of adverse events associated with triptan use in . . .
The aforementioned data collectively indicate the presence of a potential risk factor for cardiac disease in the context of triptans utilized in actual clinical practice Triptan has vasoconstrictive properties and exerts its pharmacological effects mainly by acting on the 5-HT receptor
- The Safety of Triptan Use for Migraines in the Elderly (P04. 233)
Conclusions: Triptan use in the elderly was not associated with an increased risk of death, MI, IHD or ischemic strokes However, triptan-users had fewer cardiovascular risk factors, thus it remains unclear whether triptan use is safe in elderly patients with significant cardiovascular risk factors
- Triptan: Uses, Dosage, Side Effects, FAQ - MedicinesFAQ
Triptan is also a vasoconstrictor, leading to possible adverse cardiovascular effects such as myocardial ischemia infarction, arrhythmias, cerebral and subarachnoid hemorrhage, stroke, gastrointestinal ischemia, and peripheral vasospastic reactions
- Safety of Triptans in Patients Who Have or Are at High Risk for . . .
This target trial emulation evaluated the safety of triptans in migraine patients with cardiovascular disease or multiple cardiovascular risk factors Triptans were found to significantly increase risk of MACE compared with nontriptan treatments However, the overall incidence of MACE remained low
- Real-world study of adverse events associated with triptan use in . . .
In light of the growing prevalence of migraine, it is imperative to gain a deeper understanding of the true extent of adverse events (AEs) associated with triptans in the clinical management of migraine
|
|
|